Türel O. Newer antifungal agents[J]. Expert rev anti infect ther, 2011, 9(3): 325-338.
[2]
Rapidis AD. Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment:perspectives from a maxillofacial surgeon[J]. Clin Microbiol Infect, 2009,15(Suppl 5): 98-102.
[3]
Spellberg B, Fu Y, Edwards JE Jr, et al. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice[J]. Antimicrob Agents Chemother, 2005, 49(2): 830-832.
[4]
Walsh T, Anaissie E, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America[J]. Clin Infect Dis, 2008, 46(3): 327-360.
[5]
Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents[J]. Clin Infect Dis, 2011, 52(5): 648-653.
[6]
Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis[J]. N Engl J Med, 2002, 347(6): 408-415.
[7]
Boucher HW, Groll AH, Chiou CC, et al. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy[J]. Drugs, 2004, 64(18): 1997-2020.
[8]
Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes[J].Clin Infect Dis, 2008, 46(2): 201-211.
